Yustein Jason T, Dang Chi V
Division of Pediatric Hematology-Oncology, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Curr Opin Hematol. 2007 Jul;14(4):375-81. doi: 10.1097/MOH.0b013e3281bccdee.
Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease.
Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients.
Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.
伯基特淋巴瘤是一种独特的血液系统恶性肿瘤，以其生物学特征而闻名，包括MYC癌基因的异常表达以及对强化治疗方案的需求。本综述将聚焦于这些特征，并讨论该疾病在分子生物学方面的最新进展以及不断发展的治疗选择。
分子生物学的进展为伯基特淋巴瘤的生物学特性和治疗选择提供了许多新见解。微阵列技术最近被用于定义伯基特淋巴瘤的分子基因表达特征。这一特征有助于将伯基特淋巴瘤与其他形式的非霍奇金淋巴瘤，如弥漫性大B细胞淋巴瘤区分开来。生物制剂（如利妥昔单抗）使用方面的最新进展，也在降低治疗毒性的同时，为患者提供了相当的生存结果。
伯基特淋巴瘤是一种有趣的成熟B细胞非霍奇金淋巴瘤，根据地理位置、免疫状态和患者年龄等因素具有许多独特的特征和临床变体。尽管MYC癌基因的作用已得到充分研究，但我们直到现在才开始认识到这种疾病的决定性分子特征，并利用这些进展来改善患者的治疗选择。
